Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10543257
Lentiviral vector for treating hemoglobin disorders
granted -
US 10544126
Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
granted -
US 10544145
P2X3 and/or P2X2/3 compounds and methods
granted -
US 10544467
Solid tumor methylation markers and uses thereof
granted -
US 10543192
Glycopyrrolate salts
granted -
US 10543181
Toxic aldehyde related diseases and treatment
granted -
US 10544199
Interferon alpha 2B variants
granted -
US 10543221
Beta-lactamase inhibitors, formulations, and uses thereof
granted -
US 10544232
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
granted -
US 10543481
Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation
granted -
US 10544113
Thiazolidinone compounds and use thereof
granted -
US 10544085
Oils having antibacterial activity
granted -
US 10544111
Heterocyclic compound
granted -
US 10543280
Stabilization of biomolecules using sugar polymers
granted -
US 10543282
Targeted peptide conjugates
granted -
US 10543283
Intranasal administration of guanidinylated aminoglycosides
granted -
US 10544223
Combination therapy with an anti-axl antibody-drug conjugate
granted -
US 10544392
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
granted -
US 10543268
Genetically engineered swine influenza virus and uses thereof
granted -
US 10543337
Nitric oxide delivery devices
granted -
US 10544406
Characterization of four prophage endolysins specific for clostridium perfringens
granted -
US 10544108
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 10543222
Therapy for inhibition of single-stranded RNA virus replication
granted -
US 10544418
RNAi inhibition of alpha-ENaC expression
granted -
US 10544188
Inhibitor of apoptosis protein (IAP) antagonists
granted -
US 2020030466
Stable, concentrated radionuclide complex solutions
granted -
US 2020030465
Stable, concentrated radionuclide complex solutions
granted -
US 10548863
Process to prepare treprostinil, the active ingredient in Remodulin®
granted -
US 10550407
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10550386
Monomers and oligonucleotides comprising cycloaddition adduct(s)
granted -
US 10548850
Therapeutic composition comprising insulin prepared for delivery into an intestinal tract
granted -
US 10550164
Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
granted -
US 10548879
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted -
US 10548875
Glycopyrrolate salts
granted -
US 10553318
Individual and cohort pharmacological phenotype prediction platform
granted -
US 10548987
Antibody-drug conjugates for targeting CD56-positive tumors
granted -
US 10550156
Ang (1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 10548856
Compounds and methods for modulating serotonin receptors in the periphery
granted -
US 10548970
Human rotavirus G9P[6] strain and use as a vaccine
granted -
US 10548964
Antigens and vaccines directed against human enteroviruses
granted -
US 10548890
Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
granted -
US 10548886
Methods of treatment using a JAK inhibitor compound
granted -
US 10548883
Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
granted -
US 10548860
HIF-1 modulator paint formulation and uses thereof
granted -
US 10548302
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
granted -
US 10548889
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 10548877
Aromatic ring compound
granted -
US 10548948
Methods of treating fungal infections
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.